A Phase 3 clinical trial (NCT06192108) comparing dapagliflozin with orforglipron in adult participants with Type 2 Diabetes completed on 2025-09-26. The study enrolled 962 participants to assess the safety and efficacy of orforglipron versus dapagliflozin for improving glycemic control.
Background
Dapagliflozin is a medication used in the treatment of Type 2 Diabetes. This particular study investigated its role as a comparator against orforglipron, another intervention for adults with Type 2 Diabetes who have inadequate glycemic control while on metformin.
Trial design
The study, identified as NCT06192108, was a Phase 3 trial. It enrolled 962 adult participants diagnosed with Type 2 Diabetes who had inadequate glycemic control despite using metformin. The trial's main purpose was to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control. The study involved interventions with both orforglipron and dapagliflozin.
What this means
The completion of this Phase 3 trial signifies a step forward in the evaluation of orforglipron against dapagliflozin for managing Type 2 Diabetes. Clinicians and researchers will await the publication of the study's safety and efficacy data to understand the comparative profile of these interventions for patients with inadequate glycemic control on metformin.
Source
The information regarding the completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06192108, titled "A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin," indicated its completion on 2025-09-26 on clinicaltrials.gov.